Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Signaling pathways in renal cell carcinoma.

Banumathy G, Cairns P.

Cancer Biol Ther. 2010 Oct 1;10(7):658-64. doi: 10.4161/cbt.10.7.13247. Review.

2.

Molecular basis for the treatment of renal cell carcinoma.

Suárez C, Morales R, Muñoz E, Rodón J, Valverde CM, Carles J.

Clin Transl Oncol. 2010 Jan;12(1):15-21. doi: 10.1007/s12094-010-0461-4. Review.

PMID:
20080466
3.

Pathways of dysregulation in renal cell carcinoma: rational approaches to development of novel treatment.

Khasawneh MK, Bukowski RM.

Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S7-S18. Review.

PMID:
17239285
4.

Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.

Su D, Singer EA, Srinivasan R.

Curr Opin Oncol. 2015 May;27(3):217-23. doi: 10.1097/CCO.0000000000000186. Review.

PMID:
25811348
5.
6.

Targeting the Met signaling pathway in renal cancer.

Giubellino A, Linehan WM, Bottaro DP.

Expert Rev Anticancer Ther. 2009 Jun;9(6):785-93. doi: 10.1586/era.09.43. Review.

7.

Oncotargets in different renal cancer subtypes.

Moch H, Montironi R, Lopez-Beltran A, Cheng L, Mischo A.

Curr Drug Targets. 2015;16(2):125-35. Review.

PMID:
25619751
8.

Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma.

Reuter CW, Morgan MA, Grünwald V, Herrmann TR, Burchardt M, Ganser A.

World J Urol. 2007 Mar;25(1):59-72. Review.

PMID:
17340158
9.

Understanding the importance of smart drugs in renal cell carcinoma.

Patard JJ, Rioux-Leclercq N, Fergelot P.

Eur Urol. 2006 Apr;49(4):633-43. Review.

PMID:
16481093
10.

Tumor biology and prognostic factors in renal cell carcinoma.

Finley DS, Pantuck AJ, Belldegrun AS.

Oncologist. 2011;16 Suppl 2:4-13. doi: 10.1634/theoncologist.2011-S2-04. Review.

11.

Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.

Mulders P.

BJU Int. 2009 Dec;104(11):1585-9. doi: 10.1111/j.1464-410X.2009.08987.x. Review.

12.

Chemokines as therapeutic targets in renal cell carcinoma.

Reckamp KL, Strieter RM, Figlin RA.

Expert Rev Anticancer Ther. 2008 Jun;8(6):887-93. doi: 10.1586/14737140.8.6.887. Review.

13.

Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma.

Sasamura H, Takahashi A, Miyao N, Yanase M, Masumori N, Kitamura H, Itoh N, Tsukamoto T.

Br J Cancer. 2002 Mar 4;86(5):768-73.

14.

Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.

Tie J, Desai J.

Crit Rev Oncog. 2012;17(1):51-67. Review.

PMID:
22471664
15.

Angiopoietins and non-vascular endothelial growth factor antiangiogenic targets in advanced renal cell carcinoma.

Richey SL, Hutson TE.

Cancer J. 2013 Jul-Aug;19(4):307-10. doi: 10.1097/PPO.0b013e31829d5d15. Review.

PMID:
23867511
16.

Targeted agents for the treatment of advanced renal cell carcinoma.

Stadler WM.

Cancer. 2005 Dec 1;104(11):2323-33. Review.

17.

Optimizing recent advances in metastatic renal cell carcinoma.

Courtney KD, Choueiri TK.

Curr Oncol Rep. 2009 May;11(3):218-26. Review.

PMID:
19336014
18.

The place of VEGF inhibition in the current management of renal cell carcinoma.

Nathan P, Chao D, Brock C, Savage P, Harries M, Gore M, Eisen T.

Br J Cancer. 2006 May 8;94(9):1217-20. Review.

19.

Targeting angiogenesis in renal cell carcinoma.

Posadas EM, Limvorasak S, Sharma S, Figlin RA.

Expert Opin Pharmacother. 2013 Nov;14(16):2221-36. doi: 10.1517/14656566.2013.832202. Review.

PMID:
23984807
20.

Perspectives in drug development for metastatic renal cell cancer.

Basu B, Eisen T.

Target Oncol. 2010 Jun;5(2):139-56. doi: 10.1007/s11523-010-0149-2. Review.

PMID:
20689997
Items per page

Supplemental Content

Support Center